Indo Amines Ltd Valuation Shift Signals Renewed Price Attractiveness

Valuation Metrics Show Positive Recalibration

As of 29 May 2026, Indo Amines Ltd trades at a price of ₹138.70, up 3.12% from the previous close of ₹134.50. The stock’s 52-week range spans from ₹82.00 to ₹176.00, indicating a recovery from lows but still below its peak. The company’s price-to-earnings (P/E) ratio currently stands at 12.93, a figure that has contributed to the upgrade in its valuation grade from very attractive to attractive. This P/E is significantly lower than many of its specialty chemical peers, such as Stallion India (47.84), Sanstar (60.75), and Titan Biotech (69.12), underscoring Indo Amines’ relative price appeal.

Alongside the P/E, the price-to-book value (P/BV) ratio is at 2.61, which remains reasonable given the company’s return on equity (ROE) of 20.22%. This ROE figure suggests efficient capital utilisation, supporting the valuation premium relative to book value. The enterprise value to EBITDA (EV/EBITDA) ratio of 10.69 further confirms the stock’s attractive valuation stance, especially when compared to peers like Sanstar (51.83) and Titan Biotech (56.33), which trade at much higher multiples.

Comparative Peer Analysis Highlights Relative Value

Within the specialty chemicals sector, Indo Amines’ valuation metrics stand out for their moderation. While some peers such as Nitta Gelatin (P/E 15.31, EV/EBITDA 9.67) and Jyoti Resins (P/E 15.93, EV/EBITDA 11.08) are also expensive, Indo Amines offers a more balanced risk-reward profile. Notably, companies like TGV Sraac and Gulshan Polyols are rated very attractive with lower P/E ratios of 9.22 and 26.05 respectively, but Indo Amines’ PEG ratio of 0.35 indicates undervaluation relative to earnings growth, a metric where many peers show zero or higher values.

Indo Amines’ micro-cap status means it is less followed by institutional investors, which can lead to valuation inefficiencies. The company’s return on capital employed (ROCE) of 14.91% also supports its operational efficiency, reinforcing the case for its current valuation upgrade.

Stock Performance Outpaces Sensex Over Medium to Long Term

Indo Amines has delivered robust returns relative to the benchmark Sensex across multiple time horizons. Over the past one week, the stock surged 9.43%, vastly outperforming the Sensex’s modest 0.73% gain. The one-month return is even more striking at 21.71%, compared to the Sensex’s decline of 1.86%. Year-to-date, Indo Amines has appreciated 7.56%, while the Sensex has fallen 10.97%, highlighting the stock’s resilience amid broader market weakness.

Longer-term performance also favours Indo Amines. Over three years, the stock has returned 30.01%, outpacing the Sensex’s 21.39%. The five-year return of 70.55% significantly exceeds the Sensex’s 48.43%. Most impressively, over a decade, Indo Amines has delivered a staggering 596.98% return, dwarfing the Sensex’s 184.64% gain. These figures underscore the company’s capacity to generate shareholder value over sustained periods despite its micro-cap status.

Financial Health and Dividend Yield

Indo Amines’ dividend yield remains modest at 0.35%, reflecting a focus on reinvestment and growth rather than high payout. The company’s EV to capital employed ratio of 1.93 and EV to sales of 1.13 indicate efficient asset utilisation and reasonable valuation relative to sales. These metrics, combined with solid profitability ratios, suggest a financially sound business with scope for further operational leverage.

Implications of Valuation Upgrade for Investors

The upgrade in Indo Amines’ valuation grade from very attractive to attractive signals a shift in market perception. While the stock remains reasonably priced, the narrowing gap between its valuation multiples and those of more expensive peers suggests growing investor confidence. This may be driven by improving fundamentals, better earnings visibility, or sector tailwinds in specialty chemicals.

Investors should note that despite the upgrade, the company retains a Hold mojo grade with a score of 64.0, reflecting a balanced outlook. The previous grade was Sell, changed on 26 May 2026, indicating a positive directional revision. Given the micro-cap classification, liquidity and volatility considerations remain pertinent for portfolio allocation.

Outlook and Strategic Considerations

Looking ahead, Indo Amines’ valuation attractiveness combined with solid returns and operational metrics positions it as a noteworthy contender within the specialty chemicals sector. The company’s PEG ratio of 0.35 suggests that earnings growth is not fully priced in, offering potential upside if growth accelerates. However, investors should weigh this against sector cyclicality and the company’s micro-cap status, which can entail higher volatility and lower analyst coverage.

In comparison to very expensive peers such as Stallion India and Titan Biotech, Indo Amines offers a more conservative entry point with a valuation that better aligns with its financial performance. The company’s ROCE of 14.91% and ROE of 20.22% reflect efficient capital deployment, which could support sustainable earnings growth and justify the current valuation upgrade.

Overall, the shift in valuation parameters marks a positive development for Indo Amines, signalling improved price attractiveness and a more favourable risk-reward profile for investors seeking exposure to the specialty chemicals industry.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →